4 profiles of patients who should be given amisulprid Review article
Article Sidebar
Published:
Mar 31, 2017
Keywords:
amisulpride, schizophrenia, negative sympthoms, positive sympthoms
Main Article Content
Abstract
The article presents 4 profiles of patients who may especially benefit from treatment with amisulpride, due to course of disease, positive and negative symptoms, their intensity and duration.
Article Details
How to Cite
Polikowska-Herman, M. (2017). 4 profiles of patients who should be given amisulprid. Medycyna Faktow (J EBM), 10(1(34), 63-64. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2197
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Blin O.: A comparative review of new antipsychotic. Can. J. Psychiatry 1999; 44: 235-244.
2. Carrière P., Bonhomme D., Lempérière T.: Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study. Eur. Psychiatry 2000; 15: 321-329.
3. Chabannes J.P., Pelissolo A., Farah S., Gerard D.: Evaluation of the efficacy and safety of amisulpride in the treatment of schizophrenia. L’Encephale 1998; 24(4): 386-392.
4. Colonna L., Saleem P., Dondey-Nouvel L. et al.: Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int. Clin. Psychopharmacol. 2000; 15: 13-22.
5. Coulouvrat C., Dondey-Nouvel L.: Safety of amisulpride: a review of 11 clinical studies. lnt. Clin. Psychopharmacol. 1999; 14: 209-218.
6. Danion J.M., Rein W., Fleurot O.: Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am. J. Psychiatry 1999, 156: 610-616.
7. Geddes J., Freemantle N., Harrison P., Bebbington P.: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
8. Kim S.W., Shin I.S., Kim J.M. et al.: Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31(7): 1504-1509.
9. Lecrubier Y., Quintin P., Bouhassira M. et al.: The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr. Scand. 2006; 114(5): 319-327.
10. Peuskens J., Lancrenon S., Rein W.: Metabolic control in schizophrenic patients treated with atypical antipsychotics: a subanalysis of a comparative trial of amisulpride and olanzapine [abstract no. P02.434]. 24th Congress of the Collegium Internationale Neuro-Psychopharmacologicum 2004; Jun 20-24, Paris.
11. Rein W., Coulouvrat C., Dondey-Nouvel L.: Safety profile of amisulpride in short- and long-term use. Acta Psychiatr. Scand. 2000; 101: 23-27.
12. Genç Y., Taner E., Candansayar S.: Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv. Ther. 2007; 24(1): 1-13.
13. Tyson P.J., Laws K.R., Flowers K.A. et al.: Cognitive function and social abilities in patients with schizophrenia; relationship with atypical antipsychotics. Psychiatry Clin. Neurosci. 2006; 60: 473-479.
2. Carrière P., Bonhomme D., Lempérière T.: Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study. Eur. Psychiatry 2000; 15: 321-329.
3. Chabannes J.P., Pelissolo A., Farah S., Gerard D.: Evaluation of the efficacy and safety of amisulpride in the treatment of schizophrenia. L’Encephale 1998; 24(4): 386-392.
4. Colonna L., Saleem P., Dondey-Nouvel L. et al.: Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int. Clin. Psychopharmacol. 2000; 15: 13-22.
5. Coulouvrat C., Dondey-Nouvel L.: Safety of amisulpride: a review of 11 clinical studies. lnt. Clin. Psychopharmacol. 1999; 14: 209-218.
6. Danion J.M., Rein W., Fleurot O.: Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am. J. Psychiatry 1999, 156: 610-616.
7. Geddes J., Freemantle N., Harrison P., Bebbington P.: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
8. Kim S.W., Shin I.S., Kim J.M. et al.: Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31(7): 1504-1509.
9. Lecrubier Y., Quintin P., Bouhassira M. et al.: The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr. Scand. 2006; 114(5): 319-327.
10. Peuskens J., Lancrenon S., Rein W.: Metabolic control in schizophrenic patients treated with atypical antipsychotics: a subanalysis of a comparative trial of amisulpride and olanzapine [abstract no. P02.434]. 24th Congress of the Collegium Internationale Neuro-Psychopharmacologicum 2004; Jun 20-24, Paris.
11. Rein W., Coulouvrat C., Dondey-Nouvel L.: Safety profile of amisulpride in short- and long-term use. Acta Psychiatr. Scand. 2000; 101: 23-27.
12. Genç Y., Taner E., Candansayar S.: Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv. Ther. 2007; 24(1): 1-13.
13. Tyson P.J., Laws K.R., Flowers K.A. et al.: Cognitive function and social abilities in patients with schizophrenia; relationship with atypical antipsychotics. Psychiatry Clin. Neurosci. 2006; 60: 473-479.